T. M. Kim

Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel

Jeemin Yim, Sungyoung Lee, Sehui Kim, Bogyeong Han et autres

ABSTRACT: Several molecular subclassifications of diffuse large B-cell lymphoma (DLBCL) with prognostic and therapeutic potential have been proposed; however, validation in diverse populations and real-world clinical settings remains limited. We investigated the genetic subtypes of Korean DLBCL using the LymphGen classifier and …

kr, Éthiopie, pr (code pays fourni par la source)

844 | PRIMAVERA: A PHASE I/II STUDY TO EVALUATE SAFETY AND EFFICACY OF THE PRMT5 INHIBITOR AZD3470 IN PARTICIPANTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES

Enrico Derenzini, Juan Pablo Alderuccio, P. Borchmann, Herv Ghesquieres et autres

clinical benefit rate (stable disease or better) via Simon's minimax two-stage design.Exploratory endpoints include assessment of effect of tafasitamab on blood-brain barrier permeability, correlation of the relationships between tumor response and mutational profile, change in CSF cytokines including IL-10 during treatment, and …

it, us, de, fr, es, kr, au, gb, se, ca (code pays fourni par la source)

583 | COMPARATIVE EFFECTIVENESS OF ODRONEXTAMAB VERSUS REAL‐WORLD SYSTEMIC THERAPIES USED IN AN EXTERNAL CONTROL ARM IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

E. Bachy, James Harnett, Stefano Luminari, Katharina Theresa Prochazka et autres

Introduction: Bronchial-associated lymphoid tissue marginal zone BALT lymphoma is a rare form of extraglandular non-Hodgkin lymphoma, accounting for Less than 1% of all non-Hodgkin lymphomas and approximately 10% of MALT

fr, us, it, at, gb, es, kr, ca (code pays fourni par la source)

158 | EPCORE DLBCL‐3: FIXED‐DURATION EPCORITAMAB MONOTHERAPY IN OLDER (≥ 75 Y), ANTHRACYCLINE‐INELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED LARGE B‐CELL LYMPHOMA (LBCL)

David Belada, M. A. Kwiatek, Juan Miguel Bergua Burgués, Franck Morschhauser et autres

cz, es, fr, de, kr, jp, be, us (code pays fourni par la source)

234 | POST HOC ANALYSIS OF OUTCOMES BY POD24 STATUS FROM THE inMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Laurie Helen Sehn, Kai Hübel, Stefano Luminari, Christian W. Scholz et autres

ca, de, it, gb, se, au, es, kr, jp, us, fr, be, cz (code pays fourni par la source)

28 | OUTCOMES FROM THE PHASE 3 inMIND STUDY OF TAFASITAMAB (TAFA) PLUS LENALIDOMIDE (LEN) AND RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

Laurie Helen Sehn, Kai Hübel, Stefano Luminari, Christian W. Scholz et autres

ca, de, it, es, gb, se, gr, au, kr, jp, us, fr, be, cz (code pays fourni par la source)

242 | LONG‐TERM EFFICACY AND SURVIVAL OUTCOMES WITH ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): 2‐YEAR FOLLOW‐UP FROM THE PHASE 2 ELM‐2 STUDY

Stefano Luminari, Michał Taszner, Geoffrey Chong, Silvana Novelli et autres

epcorþR 2 provided significantly higher ORR (95.9% vs. 83.5%;RR [95% CI] 1.15 [1.07-1.23];p < 0.001) and CR rate (88.2% vs. 52.0%;RR [95% CI] 1.70 [1.47-1.96];p < 0.001) versus tafaþR 2 .The HR for PFS for epcorþR 2 (median PFS: not reached) versus …

it, pl, au, es, kr, us, sg, gb, cn, fr (code pays fourni par la source)

425 | BIOMARKER ANALYSES OF THE INFLAMMATORY PROFILE AND MRD IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA VERSUS FOLLICULAR LYMPHOMA TREATED WITH ODRONEXTAMAB

Emmanuel Bachy, Michał Taszner, Geoffrey Chong, T. M. Kim et autres

fr, pl, au, kr, us, de (code pays fourni par la source)

335 | THE IMPACT OF CONSOLIDATION TREATMENT AFTER R‐MVP INDUCTION CHEMOTHERAPY IN PATIENTS WITH PRIMARY DIFFUSE LARGE B‐CELL LYMPHOMA OF THE CNS

Ju Hee Lee, S. Kim, Jung‐Sun Kim, T. M. Kim

Introduction: A phase I/II study was designed to evaluate the safety and efficacy of the combination of orelabrutinib, anti-PD-1 antibody, and fotemustine in patients (pts) with newly diagnosed PCNSL.The recommended phase II dose (RP2D) of orelabrutinib was established as 150 mg once …

kr (code pays fourni par la source)

Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis

Pier Luigi Zinzani, Tatyana A. Feldman, Graham P. Collins, Jasmine M. Zain et autres

heterobifunctional degraders for targeting previously undruggable targets.It is projected that higher doses of KT-333 will achieve the predicted degradation profile in tumors that may translate into clinical benefit in patients with STAT3-dependent T cell malignancies.Accrual into the study is ongoing, and analyses …

it, us, gb, au, kr, fr, se (code pays fourni par la source)

SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIAL

Catherine Thiéblemont, Yasmin H. Karimi, Wojciech J. Jurczak, Chan Yoon Cheah et autres

ICANS).CRS was predominantly low grade (48% G1-2; 3% G3) and occurred following the first full dose (cycle 1, day 15).One patient discontinued treatment due to G1 CRS.Conclusions: These data with longer follow-up reaffirm single-agent subcutaneous epcoritamab induces durable CRs with improved outcomes …

fr, us, au, dk, gb, kr, nl, sg, es (code pays fourni par la source)

TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)—A COHORT FROM THE ELM‐2 STUDY

Sang Hyun Cho, T. M. Kim, Michał Taszner, T. Y. Chen et autres

Introduction: MZL is a heterogeneous disease comprising 3 subtypes, extra-nodal MZL of mucosa-associated lymphoid tissue, nodal MZL, and splenic MZL. Treatment of R/R MZL is similar to other indolent B-cell non-Hodgkin lymphoma (B-NHL) subtypes (e.g., follicular lymphoma [FL]), comprising rituximab-based immunochemotherapy regimens …

kr, pl, tw, us, fr (code pays fourni par la source)